Has James Nininger, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,141 in general payments to James Nininger, MD across 176 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Nininger, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Nininger, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Nininger, MD

Psychiatry · New York, NYNPI 1235298530

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 46.6% of the total. Reporting peaked in 2022 at $1,633 and has fallen 68.3% since, to $517 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,141in general payments, 2019–2025

Across 176 payments — averaging $40.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
Lundbeck LLC$765
Takeda Pharmaceuticals U.S.A., Inc.$684
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$631
Otsuka America Pharmaceutical, Inc.$625
Alkermes, Inc.$406
plus $700 from 4 others

What the payments were for

Food & beverage$7,09499%
Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	74	$3,329
Lundbeck LLC	28	$765
Takeda Pharmaceuticals U.S.A., Inc.	28	$684
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	17	$631
Otsuka America Pharmaceutical, Inc.	5	$625
Alkermes, Inc.	7	$406
Sunovion Pharmaceuticals Inc.	12	$304
Teva Pharmaceuticals USA, Inc.	2	$152
Johnson & Johnson	2	$124
Pfizer	1	$120

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,141 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Medicare billing

Part B allowed, 2024

$115,171

Medicare patients

Services billed

715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ProzacFluoxetine Hcl	11	$9,401
Escitalopram Oxalate	112	$2,133
Bupropion XlBupropion Hcl	74	$1,736
Quetiapine Fumarate	86	$1,449
Clonazepam	108	$1,417
Mirtazapine	31	$1,051
Lorazepam	73	$1,021
Trazodone Hcl	57	$811
Lamotrigine	81	$793
Methylphenidate Hcl	16	$761
Venlafaxine Hcl ErVenlafaxine Hcl	15	$759
Aripiprazole	13	$704
Alprazolam	78	$569
Duloxetine Hcl	25	$510
Sertraline Hcl	27	$390

Paid to pharmacies, not to this prescriber.

Other psychiatry in New York

Manish ZinzuvadiaNew York$1.3M
Jianping ChenNew York$1.2M
Ulla Kristina LaaksoNew York$890K
Kerry SulkowiczNew York$435K
Ralph AquilaNew York$143K
Daniel KarlinNew York$101K
David StraussNew York$95K
Anissa Abi-DarghamNew York$94K
Robin McGarryNew York$69K
Nicole AllenNew York$63K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →